Rheumatoid arthritis (RA) is the most common autoimmune inflammatory arthritis in adults, affecting approximately 1.5 million Americans. RA is more common in women and may occur at any age, with peak incidence occurring at ages 50-60 years. RA is typically characterized by morning stiffness and symmetrical joint swelling of the feet, hands, and knees, although any joint (and in some cases, internal organs) may be involved. The course of RA may be complicated by cardiac, hematologic, and other extra-articular manifestations.
Interventions of Interest (subject to change):
- Adalimumab (Humira®, Abbvie)
- Certolizumab pegol (Cimzia®, UCB)
- Etanercept (Enbrel®, Amgen)
- Golimumab (Simponi®, Janssen)
- Infliximab (Remicade®, Janssen)
CD20- directed cytolytic antibody
- Rituximab (Rituxan®, Genentech)
- Abatacept (Orencia®, BMS)
- Sarilumab (Sanofi)
- Tocilizumab (Actemra®, Genentech)
- Tofacitinib (Xeljanz®, Pfizer)
- Baricitinib (Eli Lilly and Co.)
Date of Review: March 2017
The Joseph B. Martin Conference Center at Harvard Medical School
77 Avenue Louis Pasteur
Boston, MA 02115
The New England CEPAC will convene in March 2017 to discuss ICER's report on treatments for rheumatoid arthritis.
The webcast will be available at the following link beginning at 9:30AM ET: http://icer.bizvision.com/webcast/prod/83883
This report was open to public comment until February 17, 2017.
Public comments on the Draft Evidence Report.